{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:03:49Z","timestamp":1762956229340,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.prp.2020.152822","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T02:27:45Z","timestamp":1578623265000},"page":"152822","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical and pathological characteristics of bladder cancer in post brachytherapy patients"],"prefix":"10.1016","volume":"216","author":[{"given":"Sammy","family":"Au","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mira","family":"Keyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Black","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos F.","family":"Villamil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peyman","family":"Tavassoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.prp.2020.152822_bib0005","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"12","key":"10.1016\/j.prp.2020.152822_bib0010","first-page":"798","article-title":"Localized prostate cancer: treatment options","volume":"97","author":"Brawley","year":"2018","journal-title":"Am. Fam. Physician"},{"issue":"4","key":"10.1016\/j.prp.2020.152822_bib0015","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/bju.14223","article-title":"Low-dose-rate brachytherapy for the treatment of localised prostate cancer in men with a high risk of disease relapse","volume":"122","author":"Laing","year":"2018","journal-title":"BJU Int."},{"issue":"3","key":"10.1016\/j.prp.2020.152822_bib0020","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ijrobp.2006.05.016","article-title":"Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up","volume":"66","author":"Liauw","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.prp.2020.152822_bib0025","first-page":"108","article-title":"Bladder cancer after radiotherapy for prostate cancer","volume":"15","author":"Suriano","year":"2013","journal-title":"Rev. Urol."},{"issue":"5","key":"10.1016\/j.prp.2020.152822_bib0030","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.juro.2008.07.038","article-title":"Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study","volume":"180","author":"Nieder","year":"2008","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.prp.2020.152822_bib0035","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.radonc.2013.12.012","article-title":"ESTRO PgoG. Second primary cancers after radiation for prostate cancer: a systematic review of the clinical data and impact of treatment technique","volume":"110","author":"Murray","year":"2014","journal-title":"Radiother. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2020.152822_bib0040","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/cncr.22083","article-title":"Cancer incidence after localized therapy for prostate cancer","volume":"107","author":"Moon","year":"2006","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.prp.2020.152822_bib0045","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ijrobp.2009.02.011","article-title":"The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients","volume":"76","author":"Bhojani","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.prp.2020.152822_bib0050","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.juro.2006.10.071","article-title":"Bladder cancer incidence and risk factors in men with prostate cancer: results from cancer of the prostate strategic urologic research endeavor","volume":"177","author":"Boorjian","year":"2007","journal-title":"J. Urol."},{"issue":"4","key":"10.1016\/j.prp.2020.152822_bib0055","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.ijrobp.2008.05.022","article-title":"Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients","volume":"73","author":"Keyes","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.prp.2020.152822_bib0060","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.radonc.2010.09.012","article-title":"Analysis of second malignancies after modern radiotherapy versus prostatectomy for localized prostate cancer","volume":"98","author":"Huang","year":"2011","journal-title":"Radiother. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2020.152822_bib0065","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijrobp.2007.12.043","article-title":"Second primary cancer after radiotherapy for prostate cancer--a seer analysis of brachytherapy versus external beam radiotherapy","volume":"72","author":"Abdel-Wahab","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"8","key":"10.1016\/j.prp.2020.152822_bib0070","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.urolonc.2012.04.006","article-title":"The characteristics of bladder cancer after radiotherapy for prostate cancer","volume":"31","author":"Abern","year":"2013","journal-title":"Urol. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2020.152822_bib0075","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/MOU.0000000000000086","article-title":"Impact of histological variants on the outcomes of nonmuscle invasive bladder cancer after transurethral resection","volume":"24","author":"Seisen","year":"2014","journal-title":"Curr. Opin. Urol."},{"issue":"11","key":"10.1016\/j.prp.2020.152822_bib0080","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrurol.2017.125","article-title":"Characteristics and clinical significance of histological variants of bladder cancer","volume":"14","author":"Moschini","year":"2017","journal-title":"Nat. Rev. Urol."},{"issue":"3","key":"10.1016\/j.prp.2020.152822_bib0085","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur. Urol."},{"issue":"2 Suppl","key":"10.1016\/j.prp.2020.152822_bib0090","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.2307\/3578892","article-title":"Cancer incidence in atomic bomb survivors. Part II: solid tumors, 1958-1987","volume":"137","author":"Thompson","year":"1994","journal-title":"Radiat. Res."},{"issue":"7492","key":"10.1016\/j.prp.2020.152822_bib0095","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Cancer Genome Atlas Research N","year":"2014","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.prp.2020.152822_bib0100","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.prp.2020.152822_bib0105","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11912-018-0727-5","article-title":"Molecular subtypes of bladder Cancer","volume":"20","author":"McConkey","year":"2018","journal-title":"Curr. Oncol. Rep."},{"issue":"12","key":"10.1016\/j.prp.2020.152822_bib0110","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A molecular taxonomy for urothelial carcinoma","volume":"18","author":"Sjodahl","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2020.152822_bib0115","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ebiom.2016.08.036","article-title":"Meta-analysis of the luminal and basal subtypes of bladder Cancer and the identification of signature immunohistochemical markers for clinical use","volume":"12","author":"Dadhania","year":"2016","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.prp.2020.152822_bib0120","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder Cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.prp.2020.152822_bib0125","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive transcriptional analysis of early-stage urothelial carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.prp.2020.152822_bib0130","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2004.05.174","article-title":"Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma","volume":"22","author":"Chatterjee","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2020.152822_bib0135","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/jnci\/djn451","article-title":"Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer","volume":"101","author":"Margulis","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/j.prp.2020.152822_bib0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158891","article-title":"Clinicopathological and prognostic value of Ki-67 expression in bladder Cancer: a systematic review and meta-analysis","volume":"11","author":"Tian","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.prp.2020.152822_bib0145","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ijrobp.2010.05.042","article-title":"Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: seattle experience","volume":"81","author":"Sylvester","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.prp.2020.152822_bib0150","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.brachy.2012.03.006","article-title":"Radiation oncology and medical physicists quality assurance in British Columbia Cancer Agency Provincial Prostate Brachytherapy Program","volume":"12","author":"Keyes","year":"2013","journal-title":"Brachytherapy"},{"issue":"1","key":"10.1016\/j.prp.2020.152822_bib0155","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours","volume":"70","author":"Humphrey","year":"2016","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.prp.2020.152822_bib0160","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.urology.2007.03.033","article-title":"Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection","volume":"70","author":"Wasco","year":"2007","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.prp.2020.152822_bib0165","doi-asserted-by":"crossref","first-page":"18 e15","DOI":"10.1016\/j.urolonc.2014.10.001","article-title":"Contemporary bladder cancer: variant histology may be a significant driver of disease","volume":"33","author":"Monn","year":"2015","journal-title":"Urol. Oncol."},{"issue":"9\u201310","key":"10.1016\/j.prp.2020.152822_bib0170","doi-asserted-by":"crossref","first-page":"E690","DOI":"10.5489\/cuaj.3320","article-title":"CUA guidelines on the management of non-muscle invasive bladder cancer","volume":"9","author":"Kassouf","year":"2015","journal-title":"Can. Urol. Assoc. J."},{"issue":"5","key":"10.1016\/j.prp.2020.152822_bib0175","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00345-016-1934-z","article-title":"Incidence of bladder cancer after radiation for prostate cancer as a function of time and radiation modality","volume":"35","author":"Keehn","year":"2017","journal-title":"World J. Urol."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033819324641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033819324641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:40:08Z","timestamp":1759732808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033819324641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0344033819324641"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2020.152822","relation":{},"ISSN":["0344-0338"],"issn-type":[{"type":"print","value":"0344-0338"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and pathological characteristics of bladder cancer in post brachytherapy patients","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2020.152822","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152822"}}